AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
96,100
Stocks News & Analysis
stocks
Chart of the Week: CGT reform strengthens the case for dividend investing
Why dividend stocks are gaining an edge after tax reform.
stocks
Finding ASX opportunities in lofty market conditions
A widening valuation gap is revealing more discounted ASX shares with moats.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,151.60 | 33.90 | -0.37% |
| CAC 40 | 8,408.27 | 50.51 | -0.60% |
| DAX 40 | 25,460.48 | 3.53 | -0.01% |
| Dow JONES (US) | 51,594.14 | 1,153.18 | -2.19% |
| FTSE 100 | 10,908.41 | 37.39 | 0.34% |
| HKSE | 25,806.45 | 1.47 | -0.01% |
| NASDAQ | 24,442.94 | 433.97 | -1.74% |
| Nikkei 225 | 62,218.41 | 784.22 | 1.28% |
| NZX 50 Index | 13,777.41 | 199.26 | -1.43% |
| S&P 500 | 7,316.15 | 112.63 | -1.52% |
| S&P/ASX 200 | 8,992.90 | 31.90 | -0.35% |
| SSE Composite Index | 3,793.75 | 34.72 | -0.91% |